SEC Form 4 · accession 0001363763-16-000022

RespireRx Pharmaceuticals Inc. · RSPI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP & CFO · Director

Period of report

Mar 31, 2016

Accepted (ET)

Apr 4, 2016 · 5:42 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000849636

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock Options (to purchase shares of Common Stock)^F1	$0.0227	Mar 31, 2016	A	24,000,000	A	—	Mar 31, 2021	Common Stock	24,000,000	24,000,000	D
Common Stock Options (to purchase shares of Common Stock)^F2	$0.0197	holding	—	—	—	—	Aug 18, 2022	Common Stock	10,000,000	10,000,000	D
Common Stock Options (to purchase shares of Common Stock)^F3	$0.025	holding	—	—	—	—	Jun 30, 2022	Common Stock	15,000,000	15,000,000	D
Common Stock Options (to purchase shares of Common Stock)^F4	$0.05	holding	—	—	—	—	Jul 17, 2019	Common Stock	5,000,000	5,000,000	D

F1These Common Stock Options vest in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016.
F2These Common Stock Options vest in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016.
F3These Common Stock Options vest in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015.
F4These Common Stock Options vested in three equal installments on July 17, 2014, September 30, 2014 and December 31, 2014, and are all currently vested and exercisable.